Up 10%: Why the Polynovo share price is popping today

Polynovo shares are rocketing for the second day in a row…

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's looking like another strong day for ASX shares and the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. At the time of writing, the ASX 200 has gained a healthy 0.38%, putting the index back over 7,500 points. But let's discuss the Polynovo Ltd (ASX: PNV) share price.

Polynovo shares are putting the gains of the broader market to shame so far this Tuesday. At present, the ASX 200 healthcare stock is up a whopping 8.16% at $1.88 a share. That's after Polynovo stock lifted as high as $1.92 soon after market open this morning (up more than 10% at the time).

So what's going on with this healthcare company today that is resulting in these kinds of stellar share price moves?

Polynovo shares spike 10% on bumper trading result

It seems that these gains can be put down to the trading update Polynovo released yesterday during trading hours.

As we briefly touched on yesterday afternoon, this indicative trading update (covering the first half of FY2024) was probably responsible for Polynovo shares' near-10% rise for Monday's session.

It's not too hard to see why.

Polynovo told investors that its total global revenue for the first half of FY2024 came in at 48.8 million, up 65.6% from the $29.5 million recorded at this time last year.

The company also achieved a record sales revenue of $42.2 million (up 54.9%), as well as U.S. sales of $32.2 million (up 41.7%).

Rest of world sales rocketed 122.2% to $10 million.

The company also reported positive earnings before interest, tax, depreciation and amortisation (EBITDA), and a net profit after tax (NPAT) for the period. Excluding non-cash items, Polynovo achieved an underlying EBITS of $3.6 million for the period.

Polynovo chair David Williams had this to say on these numbers:

While I view profit as a 'nice to have', I am more excited by the significant near-term revenue growth possibilities from our expanding geographic footprint and the new ways surgeons have found to use our products. Profits will drop naturally out of the drive and success in expanding our geographies and products.

Given most of yesterday's strong share price gains came after Polynovo released this update, it seems that we can thank it for both those gains, and the further rise we are seeing today.

But despite these gains, the Polynovo share price remains down by 25.8% over the past 12 months.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »

A man packs up a box of belongings at his desk as he prepares to leave the office.
Healthcare Shares

Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Telix shares storm higher on big US and China news

Let's see why this biotech is getting attention on Monday.

Read more »